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Summary
 
We found that the presentation of a H-2K
 
d
 
-restricted determinant from influenza virus nucleo-
protein (NP) to T cells is strictly dependent on expression of the transporter associated with an-
tigen presentation (TAP), regardless of whether NP is expressed as a cytosolic or secreted NP
(SNP). Introducing an N-linked glycosylation site into the determinant selectively reduced
presentation of SNP. This indicates that glycosylation does not interfere with TAP-transported
peptides, and therefore that cytosolic peptides derived from SNP must have been exposed to
the glycosylation machinery of the endoplasmic reticulum (ER) before their existence in the
cytosol. Based on these findings, we propose that TAP-dependent processing of at least some
ER-targeted proteins entails the reimportation of protein from the secretory pathway to the
cytosol, where the protein is processed via the classical pathway.
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C
 
lass I molecules of the MHC function to display pep-
tides from intracellular proteins on the cell surface for
inspection by CD8
 
1
 
 T cells (T
 
CD8
 
1
 
). In most cases, pep-
tides derive from a cytosolic/nuclear pool of proteins through
the action of proteasomes or other cytosolic proteases (1), and
are delivered to class I molecules by transporter associated with
antigen presentation (TAP)
 
1
 
, the MHC-encoded peptide trans-
porter (2). Newly synthesized 
 
a
 
-
 
b
 
2
 
microglobulin hetero-
dimers associate with TAP and remain tethered until released
by a conformational alteration induced by peptide binding
(3, 4). These events occur in the endoplasmic reticulum
(ER) (5).
Although many class I binding peptides derive from cy-
tosolic or nuclear proteins, proteins targeted to the ER (per-
haps a third of all cellular proteins, and important antigens
for membrane viruses) also represent a major source of pep-
tides. Most peptides from ER-targeted proteins are pre-
sented in a TAP-dependent manner. This, in conjunction
with earlier findings that removal of the ER-insertion se-
quence from integral membrane proteins increases their an-
tigenicity (6, 7), indicates that antigenic peptides from ER-
targeted proteins are often produced by cytosolic proteases.
It remains unresolved however, to what extent this reflects
generation of peptides from defective cytosolic forms of the
protein that are not exported to the ER, as originally pro-
posed (8), versus reimportation of exported proteins to the
cytosol where they are processed as cytosolic antigens. The
latter possibility has gained credence with recent findings
from several systems that membrane-anchored and soluble
proteins and peptides can be returned to the cytosol where
they are degraded in a proteasome dependent manner (9–12).
In the present study we examine this question using Asn-
linked glycosylation (commonly termed N-linked glycosyla-
tion) as a means of determining whether the source protein
has visited the ER. N-linked glycosylation occurs exclu-
sively in the ER, where Glc
 
3
 
Man
 
9
 
GlcNac
 
2
 
 is added to Asn
residues present in the sequence Asn X Ser/Thr (
 
X
 
, any
residue except Pro). Under normal circumstances, glycosy-
 
1
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lation is believed to occur cotranslationally as proteins are
threaded through the translocon. Extrusion through the
translocon is not an absolute requirement, however, since
synthetic peptides can also be glycosylated when delivered
to the ER via TAP (13–16). Protein conformation can in-
fluence glycosylation, since potential glycosylation sites present
on exported proteins are not always used.
Glycosylation of class I binding peptides is likely to mod-
ify or destroy peptide antigenicity. Depending on the ori-
entation of the glycosylated Asn in the class I binding
groove, addition of the oligosaccharide (which is bulkier
than the typical class I binding peptide) would be expected
to prevent either class I binding or T cell recognition. In-
deed, the addition of N-linked oligosaccharides to MHC
class II–associated peptides has been found to abolish pre-
sentation to T
 
CD4
 
1
 
 (17–19). More directly, addition of O-
or N-linked oligosaccharides to MHC class I–associated
peptides either greatly reduces binding to class I molecules
or interferes with recognition by T
 
CD8
 
1
 
, depending on the
orientation of the modified residue (20). N-linked oli-
gosaccharides can be removed by peptide 
 
N
 
 glycanase
(PNGase); this results in the conversion of the oligosaccha-
ride modified residue from Asn to Asp. Skipper et al. found
just such a conversion in a peptide derived from an ER-tar-
geted protein (21). Although the TAP dependence of pep-
tide presentation was not reported in this study, it is
thought that PNGase is located exclusively in the cytosol/
nucleus (22), which, if true, would mean that peptides were
derived from glycosylated protein returned to the cytosol.
In the present study, we provide evidence that this ER to
cytosol pathway does indeed contribute to the generation
of antigenic peptides from proteins cotranslationally tar-
geted to the secretory pathway.
 
Materials and Methods
 
Recombinant Vaccinia Viruses.
 
Recombinant vaccinia viruses
(rVVs) expressing K
 
d
 
, TAP (1 and 2), and influenza virus nucleo-
protein (NP) have been described (23, 24). A rVV expressing
ICP47 (25) was provided by B. Rouse (University of Tennessee,
Knoxville, TN). The full-length NP gene modified by standard
molecular genetic methods to encode molecules listed in Table 1
was inserted into the thymidine kinase locus of vaccinia viruses
(VVs) by homologous recombination as described using the
pSC11 plasmid to express foreign proteins under the control of
the VV p7.5 early/late promoter (26). NP was directed to the
secretory pathway using the signal sequence from 
 
b
 
 interferon
(27). The NP-coding sequences of all of the rVVs were verified
by sequencing PCR-amplified copies of full-length NP genes iso-
lated from the rVV.
 
Mice and Cytotoxicity Assays.
 
6–8-wk-old BALB/cByJ (H-2
 
d
 
)
and CBA/J (H-2
 
k
 
) mice were obtained from Jackson Labs (Bar
Harbor, ME). Mice were immunized with PR8 by intraperito-
neal injection, and with rVV by intravenous injection. Target
cells were infected with viruses as described previously (28). To
generate T
 
CD8
 
1
 
, splenocytes derived from animals immunized
with viruses 2–6 wk previously were stimulated in vitro for 7 d
with either antigenic peptides at 1 
 
m
 
g/ml or virus-infected autol-
ogous splenocytes as described (29). In some cases, T
 
CD8
 
1
 
 lines
were used in place of secondary cultures. Lines were propagated
by weekly stimulation with L929-K
 
d
 
 cells that had been incu-
bated for 3 h at 37
 
8
 
C with IMDM supplemented with 20 
 
m
 
g/ml
human 
 
b
 
2
 
-microglobulin (Sigma Chemical Co., St. Louis, MO)
and 1.2 
 
m
 
g/ml synthetic peptide, fixed for 10 min at room tem-
perature with 0.5% paraformaldehyde in PBS, and washed by
three consecutive 30-min incubations with IMDM at 37
 
8
 
C. 1–2 d
after stimulation with cells, fresh IMDM supplemented with 10%
(vol/vol) supernatant from rat splenocytes stimulated with Con A
was added. This stimulation protocol was repeated weekly. Mi-
crocytotoxicity assays were performed as previously described
(28). Where indicated, brefeldin A (BFA; Sigma Chemical Co.)
was added to cells at a concentration of 5 
 
m
 
g/ml before assay and
at a concentration of 2.5 
 
m
 
g/ml during the cytotoxicity assay to
block further antigen presentation (29). Data are expressed as per-
cent-specific release defined as:
Experimental release 
 
2
 
 medium release/
total release 
 
2
 
 medium release 
 
3
 
 100.
 
Synthetic Peptides.
 
Synthetic peptides were provided by the
Biological Resources Branch (National Institute of Allergy and
Infectious Diseases, Bethesda, MD). Glycopeptides were pro-
duced as described (18). All peptides were purified by HPLC and
analyzed by mass spectroscopy to confirm purity and mass.
 
Biochemical Procedures.
 
2 
 
3
 
 10 
 
7
 
 L929 cells infected for 1 h
with VV were incubated in 2 ml Met-free DMEM for 30 min at
37
 
8
 
C. After adding 200 
 
m
 
Ci [
 
35
 
S]methionine in 200 
 
m
 
l Met-free
DMEM, cells were incubated for an additional 10 min at 37
 
8
 
C.
After washing with PBS, cells were incubated for 20 min at 0
 
8
 
C
with 0.14 M NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM
PMSF, and 10 mM Tris HCl, pH 7.4, and the nuclei were pellet-
ted by centrifugation at 15,000 
 
g.
 
 Supernatants were incubated
with protein A–Sepharose preloaded with the anti-NP mAb
H16-L10. After extensive washing, beads were boiled in sample
buffer according to Laemmli (30), or in 0.1 M sodium acetate, 3
mM EDTA, and 0.25% SDS, pH 6. In the latter case, samples
were split in half, incubated overnight at 37
 
8
 
C with or without 2
mU endo-
 
b
 
-
 
N
 
-acetylglucosaminidase (endo H). All samples
were analyzed by SDS-PAGE according to Laemmli. After fix-
ing, gels were dried under vacuum and exposed to Phosphorim-
ager screens (Molecular Dynamics, Sunnyvale, CA), which were
imaged using the associated hardware and software. For quantita-
tion of viral gene expression in cells used for the microcytoxicity
assay, an aliquot of 10
 
6
 
 cells was removed, incubated in methio-
nine-deficient medium for 15 min, and labeled with [
 
35
 
S]-methio-
nine for 45 s. Labeling was terminated by the addition of Laemmli
sample buffer heated to 100
 
8
 
C. Samples were analyzed by SDS-
PAGE, and the amount of protein in fixed gels determined using
a Phosphorimager (Molecular Dynamics). Images of gels were ar-
ranged and labeled with Adobe Photoshop (Adobe Systems,
Mountain View, CA) and printed with a Fujix 3000 pictography
digital printer (Fuji Photo Film USA, Elmsford, NY).
 
Results
 
Experimental Strategy and Characterization of Antigenic Pep-
tides.
 
As a model antigen we used influenza virus NP syn-
thesized by rVV. NP is synthesized on free ribosomes in the
cytosol and efficiently translocated to the nucleus due to a nu-
clear localization sequence. In H-2
 
d
 
 mice, the T
 
CD8
 
1
 
 response
to NP focuses on an immunodominant K
 
d
 
-restricted pep-
tide located at residues 147–155 (TYQRTRALV). Con-
version of the Gln
 
149
 
 to Asn creates a N-linked glycosyla- 
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tion site. To study the effects of glycosylation on antigen
processing, we produced rVVs expressing NP with Gln
 
149
 
or Asn
 
149
 
 directed to the ER by appendage of a NH
 
2
 
-ter-
minal ER insertion sequence (termed secreted NP [SNP];
Table 1). We controlled for effects of the Gln
 
149
 
®
 
Asn sub-
stitution on peptide liberation, class I binding, and TCR
recognition by using rVVs expressing the same proteins in
the cytosol. To examine whether any alterations in presen-
tation of SNP
 
N
 
 are related to glycosylation, we produced
rVVs expressing cytosolic or ER-targeted NPs in which
the glycosylation site created by the Gln
 
149
 
®
 
Asn substitu-
tion is destroyed by converting Thr
 
151
 
 to Ala (Table 1).
Obviously, for this to be a useful strategy, the amino acid
substitution alone cannot adversely affect the binding of the
peptides to K
 
d
 
. This was examined in two ways. First,
RMA/S K
 
d
 
 cells incubated at 26
 
8
 
C to accumulate cell-sur-
face peptide–receptive molecules were exposed to decreas-
ing amounts of peptides for an hour at 26
 
8
 
C, and then for 2 h
at 37
 
8
 
C to denature class I molecules lacking peptides. BFA
was included with peptides to prevent the transport of ad-
ditional K
 
d
 
 molecules to the cell surface. Conformed class I
molecules were detected using the mAb SF1.1.1 conju-
gated to FITC. The peptide concentration required to pre-
serve half of the cell-surface K
 
d
 
 molecules provides an ap-
proximation of peptide affinity for K
 
d
 
. This revealed that
the Asn
 
149
 
- and Asn
 
149
 
Ala
 
151
 
-containing peptides have K
 
a
 
s
approximately 2.5–3-fold higher than the wild-type pep-
tide (K
 
a
 
 
 
5
 
 1/[peptide concentration], yielding values for
variant and wild-type peptides, respectively, of 1–1.2 
 
3
 
 10
 
7
 
M
 
2
 
1
 
 versus 4.2 
 
3
 
 10
 
6
 
 M
 
2
 
1
 
) (Fig. 1). By contrast, a peptide
containing Asp
 
149
 
 (which would result from PNGase-medi-
ated removal of the N-linked oligosaccharide from Asn
 
149)
was bound with an estimated Ka 230-fold lower than the
wild-type peptide (1.8 3 104 M21).
The relative affinities of the peptides were confirmed by
examining the thermal stability of cell-surface Kd molecules
loaded with a saturating concentration of peptide at 268C
and incubated at 378C for up to 8 h in BFA in the absence
of peptides. This provides a measure of the off-rate for pep-
tide binding, which is the major factor in peptide affinity
for class I molecules. Kd molecules were most efficiently
stabilized by the N149-containing peptides, and were only
marginally stabilized by the Asp149-containing peptide.
In the experiments that follow, we used TCD81 popula-
tions or lines raised to the wild-type sequence as a measure
of presentation of the 147–155 determinant from the dif-
ferent cytosolic or ER-targeted NPs. The effects of the
amino acid substitutions on peptide antigenicity varied some-
what with the TCD81 population or line used. In two of the
experiments described below, the Asn149- and Asn149Ala151-
containing peptides sensitized target cells for lysis by NP-
specific TCD81 with similar or slightly greater efficiencies
than the wild-type peptide (see Figs. 3 and 5). The Asp149-
containing peptide routinely required 100–1,000 times the
concentration of Gln149- or Asn149-containing peptides to
achieve a similar level of lysis (not shown).
To confirm that attachment of an N-linked oligosaccha-
ride to Asn149 abolishes peptide antigenicity, we coupled
Asn149 in the TYNRTRALV synthetic peptide to the di-
saccharide maltobiose. This resulted in at least a 5 log10-fold
reduction in the capacity of the peptide to sensitize cells for
lysis (not shown). Oligosaccharides added in the ER are
Table I. rVVs Used in This Study
Designation Foreign gene product
VV-NP Full-length NP
VV-NPN Full-length NP, Gln149® Asn149
VV-NPNRA Full-length NP, Gln149® Asn149, Thr151®Ala151
VV-SNP b-IFN leader, full-length NP
VV-SNPN b-IFN leader, full-length NP,Gln149®Asn149
VV-SNPNRA b-IFN leader, full-length NP,Gln149®Asn149,
Thr151®Ala151
Figure 1. Peptide binding to
Kd. RMA/S Kd cells incubated
overnight at 268C were incu-
bated for an additional hour with
the indicated concentration of
peptide and BFA (5 mg/ml), and
then at 378C for 2 h (left). Alter-
natively, cells were incubated
with 10 mM peptide and BFA,
extensively washed, and then in-
cubated at 378C for the indicated
time in the absence of peptide
(right). The amount of cell-sur-
face Kd was determined using the
fluorescein-conjugated mAb
SF1.1.1 (PharMingen, San Di-
ego, CA). The concentration of
peptide required for protection
of one half of the Kd molecules
was determined by linear extrap-
olation of the mean channel flu-
orescence values.482 Endoplasmic Reticulum to Cytosol Antigen-processing Pathway
much larger than this disaccharide, consisting of between
10 and 14 saccharide subunits, depending on the degree of
modification by ER glucosidases and mannosidases (31),
and would be expected to interfere to an even greater ex-
tent than maltobiose with peptide binding to class I mole-
cules or interaction with the TCR. These findings demon-
strate that (a) we can meaningfully compare presentation of
variant and wild-type peptides using TCD81 effectors raised
to the wild-type sequence, and, (b) glycosylation will de-
stroy peptide antigenicity due either to the presence of the
N-linked oligosaccharide, or after its removal by PNGase,
the poor antigenicity of the Asp149 containing peptide.
Characterization of SNP. The function of the ER-tar-
geting sequence was confirmed by SDS-PAGE analysis of
total cell extracts of rVV-infected cells metabolically la-
beled with [35S]methionine. As seen in Fig. 2 A, the se-
creted forms of NP migrated more slowly than the cytoso-
lic/nuclear forms. SNP and SNPNRA comigrated, whereas
SNPN migrated more slowly, which is consistent with the
existence of one site for N-linked glycosylation in SNP and
SNPNRA (NP has a natural glycosylation site at position 21)
and two sites in SNPN. This was confirmed by digestion of
immunocollected SNP and SNPN with endo H, which
eradicated the difference in mobility between the ER-tar-
geted and nontargeted forms of NP (Fig. 2 B). It is impor-
tant to note that all three forms of SNP were efficiently de-
livered to the ER and glycosylated at all potential sites,
since we did not detect, by either immunoprecipitation or
by Western blotting (not shown), full-length forms that
were nonglycosylated or partially glycosylated. Upon pro-
longed chasing at 378C, all three forms of SNP became
endo H–resistant and were secreted into the medium with
a t1/2 of z3 h (not shown). 
These biochemical findings were confirmed using anti-NP
mAbs in indirect immunofluorescence of fixed and perme-
abilized rVV-infected cells (not shown). Non-ER–targeted
forms were largely localized to the nucleus as expected,
whereas secreted forms were located in the ER and Golgi
complex. Upon prolonged infection (16 h), weak NP-spe-
cific staining was detected in the nuclei of cells expressing
SNP, SNPN, or SNPNRA (“SNPs”).
Together, these findings demonstrate that (a) SNPs are
efficiently targeted to the ER, (b) all potential glycosylation
sites are used in SNPs to within the limits of detection, and
(c) a minor portion of SNPs make their way to the nucleus.
Effect of Gln149®Asn Substitution on NP/SNP Antigenicity
and Immunogenicity. The efficiency of generating the
NP147-155 peptide from the six different forms of NP was
determined using a NP-specific TCD81 line that recognizes
the wild type, Asn149- and Asn149Ala151-containing peptides
with similar efficiency (Fig. 3, inset). The efficiency of pep-
tide generation was estimated by adding BFA to L-Kd cells
at increasing intervals after infection with rVVs (Fig. 3; 32).
As with other proteins, targeting NP to the ER reduced
the efficiency of peptide generation. Modification of amino
acids 149 or 151 had little effect on presentation of cytoso-
lic NP. The same alterations, however, had clear effects on
presentation of SNP. The Gln149®Asn substitution signifi-
cantly reduced presentation of SNP. The similar levels of
presentation of SNPNRA and SNP indicates that glycosyla-
tion of Asn149 is responsible for decreased presentation of
SNPN relative to SNP.
To eliminate the possibility that the differences in anti-
gen presentation reflected differences in levels of expression
of the various antigens (and not real differences in antigen
processing), we quantitated the amounts of NP produced
by the target cells used in this experiment. Cells were radio-
labeled with [35S]methionine for 45 s and immediately im-
mersed in boiling SDS-PAGE sample buffer. This method
allows recovery of virtually all of the biosynthesized pro-
teins, and not just those extracted into relatively mild de-
tergents that are capable of binding antibody (the technique
most commonly used to quantitate antigen expression). SDS-
PAGE of extracts revealed that newly synthesized NP could
be easily detected due to the strength of the VV p7.5 pro-
moter combined with the ability of VV to shut down host
cell protein synthesis. As seen in Fig. 2 A, the difference in
presentation between the secreted forms of NP cannot be
attributed to differences in levels of expression. Indeed, in-
creasing the amount of SNPN synthesized by increasing the
virus dose by threefold (SNPN
High) did not increase presen-
tation to TCD81 (Fig. 3). NP-specific TCD81 from H-2k
mice recognize residues 50–57 in association with Kk (33).
Unlike the Kd-restricted determinant, the presentation of
NP50-57 was not adversely affected by the Gln149®Asn sub-
Figure 2. Characterization of
SNP. (A) Aliquots of the target
cells used in Fig. 3 A were re-
moved 90 min after infection
and radiolabeled with [35S]me-
thionine. Total cell extracts were
analyzed by SDS-PAGE. Radio-
activity in the fixed and dried
gels was located using a Phos-
phorimager that was used to
quantitate the radioactivity in the
NP and SNP band, which are
clearly evident. The total
amounts of counts per lane were
normalized to allow for differ-
ences in sample preparation, and
the corrected amount of radioac-
tivity present in the same region
of an extract prepared from cells
infected with a control VV was
subtracted from each value. The
adjusted amounts of various
forms of NP synthesized relative
to NP (5 1.00) are: NPN, 1.65;
NPNRA, 2.16; SNP, 1.24;
SNPN, 1.72; SNPN high, 2.23;
and SNPNRA, 1.82. (B) NP
present in detergent lysates from
cells infected with rVV express-
ing various forms of NP was col-
lected using protein A agarose
preloaded with the NP-specific
mAb H16-L10, digested with
endo H and analyzed by SDS-
PAGE.483 Ba ík et al. c ˇ
stitution in SNP (Fig. 4). In fact, VV-SNPN–infected cells
were recognized at slightly higher levels by Kk-restricted
TCD81 than cells expressing SNP, whereas the very same target
cells gave the reverse hierarchy of lysis using Kd-restricted
TCD81. This provides functional evidence that the dimin-
ished recognition of VV-SNPN–infected cells relative to
VV-SNP–infected cells is not related to diminished levels
of SNPN expression. Moreover, this experiment indicates
that the inhibitory effect of glycosylation on SNP antigen
processing is limited to the determinant containing the gly-
cosylation site.
We next compared the presentation of the various rVVs
to primary TCD81 in vivo by determining the amount of vi-
rus required to prime for secondary in vitro responses to
synthetic peptides (Fig. 3 B). Targeting NP to the secretory
pathway did not significantly alter its immunogenicity. Re-
markably, introducing the Gln149®Asn substitution into SNP
decreased the immunogenicity of the rVV 100-fold relative
to the other viruses (in additional experiments we detected
priming after inoculation with 106 plaque-forming units/
mouse [not shown]). This effect was specific for the se-
creted form, since the same substitution actually increased
the immunogenicity of cytosolic NP 10-fold. The low im-
munogenicity of VV-SNPN cannot be attributed to poor
infectivity in vivo since it primed for VV-specific responses
with similar efficiency as the other rVVs (not shown).
These findings demonstrate that the presence of an N-linked
glycosylation site in a secreted protein specifically affects its
antigenicity and immunogenicity, presumably due to the
attachment of an N-linked oligosaccharide in the ER. Cre-
ation of the same site in a cytosolic version of the protein
has no significant effect on antigenicity.
TAP Dependence of Antigen Presentation. The involvement
of TAP in the presentation of NP, NPN, SNP, and SNPN
was examined using T2-Kd cells, a TAP-deficient human
lymphoblastoid cell line expressing Kd from a transfected
gene (34; Fig. 5 A). None of the corresponding rVVs were
able to sensitize T2-Kd cells for lysis by NP-specific TCD81.
The precise hierarchy of presentation of the various gene
products observed in L-Kd cells was faithfully restored,
however, by coinfection with VV-TAP (1 and 2), which
encodes both human TAP subunits (35). Lysis of SNPN-
expressing cells was at levels less than half that observed
with SNP. This cannot be attributed to less efficient recog-
nition of the Asn149-containing peptide by the TCD81 line
used since NPN was presented slightly more efficiently than
NP and the synthetic peptides were recognized with simi-
lar efficiency. Nor can it be attributed to decreased expres-
sion of SNPN relative to SNP. As in the previous experi-
ment, cells were briefly radiolabeled and the expression of
NPs quantitated after SDS-PAGE of whole cell lysates.
This demonstrated that SNPN was expressed in similar
Figure 3. Antigenicity and
immunogenicity of rVVs ex-
pressing various forms of NP.
(A) L-Kd cells were infected for
the indicated times with the
rVVs indicated before BFA was
added and then maintained con-
tinuously. After 51Cr labeling,
cells were incubated for 6 h at an
E/T of 5:1 with a TCD81 line pro-
duced by PR8 in vitro secondary
restimulation of splenocytes de-
rived from mice inoculated with
VV-NP. The recognition of syn-
thetic peptides incubated with cells
at the indicated concentration is
shown in the inset. (B) Splenocytes from BALB/c mice immunized with the indicated rVV 3 wk previously were restimulated in vitro for 7 d with the
homologous synthetic peptide (TYQRTRALV or TYNRTRALV), and tested for their ability to lyse P815 cells sensitized with the same peptide. Cul-
tures were used at the same dilution. All values have been corrected for background lysis values obtained with cells in the absence of added synthetic pep-
tides.
Figure 4. Comparison of pre-
sentation of NP147-155 to NP50-57.
L-Kd cells infected with the rVV
indicated were tested for lysis by
TCD81 lines specific for NP147-155
or NP50-57 at the indicated E/T.484 Endoplasmic Reticulum to Cytosol Antigen-processing Pathway
amounts to SNP (Fig. 5 legend). To eliminate the possibil-
ity that a minor population of cells synthesized most of the
antigen, NP expression was examined by immunoperoxi-
dase staining of fixed and permeabilized target cells. As seen
in Fig. 5, a similar percentage of cells expressed the various
forms of NP (SNPN was actually detected in a greater per-
centage of cells than SNP).
These findings demonstrate that the TAP-dependent
presentation of the 147-155 peptide derived from SNP is
blocked by glycosylation. TAP has recently been shown to
directly bind to class I molecules (3, 4), and its potential as a
molecular chaperone in class I folding has been suggested
(36). Thus, it is possible that the TAP dependence of pre-
sentation of the NP147-155 determinant reflects a role for TAP
in facilitating the association of Kd with the free peptide in
the ER lumen, and not the transport of 147-155 peptide
from the cytosol. To examine this possibility, we used an
rVV expressing the herpes simplex virus protein ICP47 to
specifically inhibit the transport function of TAP (23, 37–
40). Coexpression of TAP with ICP47 blocked the TAP-
mediated rescue of both NP and SNP (Fig. 5 B).
These findings demonstrate that the 147-155 determi-
nant produced from SNP is delivered to class I molecules
by TAP from the cytosol, and that this presentation is par-
tially blocked by glycosylation.
Discussion
Based on its dependence on TAP-mediated peptide trans-
port, we conclude that antigenic peptides from SNP are
produced in the cytosol. Substituting Asn for Gln149 in SNP
specifically decreases the immunogenicity and antigenicity
of the 147-155 determinant. This cannot be attributed to
negative effects of the substitution on peptide affinity for
Kd or TCR recognition. Nor can it be attributed to dimin-
ished TAP-mediated transport or liberation by cellular pro-
teases of the Asn149-containing peptide, since NPN is presented
with similar or even greater efficiency than wild-type NP.
Rather, these findings implicate glycosylation as the cause
of reduced antigenicity, which is confirmed by the en-
hanced presentation observed when the glycosylation site is
destroyed by substituting Ala for Thr151. Since the Asn149-
containing peptide in cytosolic NP is presented normally,
the effect of glycosylation on SNPN must occur before
TAP-mediated transport. This indicates that most antigenic
peptides from SNP are derived from protein that is deliv-
ered to the ER and then routed back to the cytosol where
it is processed by cytosolic proteases into peptides that are
delivered to Kd molecules via TAP.
A synthetic version of the Asn149-substituted 147-155
peptide is glycosylated in a TAP-dependent manner when
added to cells permeabilized by streptolysin O (our unpub-
Figure 5. TAP dependence
of antigen presentation. (A) T2
Kd cells coinfected with VV-
TAP (1 and 2) and the rVVs in-
dicated, or just with the rVV in-
dicated (“No TAP”) were tested
for lysis by a NP-specific TCD81
line at the E/T ratios indicated.
The recognition of synthetic
peptides incubated with cells at
the indicated concentration by
the same TCD81 line is shown in
the inset. The amount of antigen
expressed by the target cells 4 h
after infection was determined
by quantitating bands detected in
SDS-PAGE of whole cell ex-
tracts as described in Fig. 2. The
adjusted amounts of various
forms of NP synthesized relative
to NP (5 1.00) are: NPN, 1.49;
SNP, 1.01; and SNPN, 1.01. (B)
Effect of ICP47 on antigen pre-
sentation. T2 Kd cells infected
with the rVVs indicated were
tested for lysis by the TCD81 line
used in A at the indicated E/T
ratio. (C) The target cells used in
A were incubated in flat-bottom
96-well plates coated with Con
A to adhere the cells. At the con-
clusion of the 51Cr release assay,
cells were fixed by 2-min incu-
bation with acetone/methanol
(1:1) and indirectly immunoper-
oxidase stained using the H16-
L10 mAb. Video images of the stained cells were printed using a printer (UP5500; Sony, San Jose, CA), digitized by a flat bed scanner, assembled using
Adobe Photoshop software, and, printed with a digital printer (3000; Fuji Photo Film USA).485 Ba ík et al. c ˇ
lished results). Thus, we interpret the efficient presentation
NPN to indicate that the Asn149-containing peptide associ-
ates with Kd before the peptide can be glycosylated. This is
consistent with the idea that TAP delivers peptides directly
to the class I molecules they bind (3, 4). The practical im-
portance of this is that the antigenicity and immunogenicity
of peptides in cytosolic/nuclear proteins are probably not af-
fected by the presence of a consensus site for N-linked gly-
cosylation.
By contrast, the antigenicity, and particularly the immu-
nogenicity of SNP, were greatly affected by the presence of
a glycosylation site, indicating that glycosylation can have
a major negative effect on the antigenicity of peptides in
ER-targeted proteins. The disproportionate effect of the
Gln149ÞAsn substitution on SNP immunogenicity relative
to its effect on antigenicity indicates that presentation of
antigen to primary T cells in vivo is fundamentally different
from in vitro presentation. This may reflect differences in
antigen processing in the APCs used in vivo versus the var-
ious tumor cells we have used. An intriguing possibility
that we favor is that in vivo presentation of SNP relies
largely on processing of exogenous antigen scavenged from
infected cells by professional APCs (41). Exogenous anti-
gens would consist of the metabolically stable proteins pro-
duced by cells, and in this case, the very large difference
between presentation of SNP and SNPN would be ex-
pected based on the high efficiency of glycosylation of
Asn149.
The present results do not distinguish in which secretory
organelle egress of SNP to the cytosol occurs (anywhere
from ER to lysosomes is possible). Cells are able to present
exogenous antigens in a TAP-dependent manner, due to
release of pinocytosed material to the cytosol. This pathway
is largely limited to phagocytosing cells, however. More-
over, in additional experiments (not shown), we found that
presentation of SNP could not be attributed to uptake of
secreted material, since coincubation of VV-SNP–infected
cells with 51Cr-labeled uninfected cells during the course of
a 6-h cytotoxicity assay did not result in the lysis of unin-
fected cells (not shown). It was recently shown that two
cytomegalovirus proteins, US2 and US11, have the re-
markable ability to transport newly synthesized class I mol-
ecules from the ER to the cytosol, probably by inducing
reverse translocation through the translocon (10, 11). The
authors proposed that cytomegalovirus takes advantage of a
constitutive operating cellular pathway that underlies the
phenomenon of ER-associated degradation of defective or
unassembled proteins. We propose that SNP is reimported
from the ER to the cytosol via the same pathway.
The negative effect of glycosylation on peptide antige-
nicity could have several causes. First, if the oligosaccharide
is not removed, peptide antigenicity would be eradicated
by interference with TAP-mediated transport, Kd binding,
or TCR recognition. Second, removal of the oligosaccha-
ride by cytosolic PNGase would create an Asp149-substi-
tuted peptide with low affinity for Kd. In additional experi-
ments, we found that this peptide sensitizes cells 1,000-fold
less efficiently than the wild-type peptide for lysis mediated
by TCD81 raised to NP, and that these TCD81 do not recog-
nize cells expressing rVV encoded cytosolic or ER-targeted
Asp149-containing peptides (our unpublished results). Thus,
removal of the glycan would destroy peptide antigenicity as
surely as its nonremoval.
The inhibitory effect of glycosylation on in vitro or in
vivo presentation of SNP was incomplete. Based on the ar-
gument presented in the preceding paragraph, the residual
presentation of SNPN is almost certainly due to incomplete
glycosylation of Asn149. Although we cannot eliminate the
possibility that a small amount of SNPN escapes glycosyla-
tion at Asn149, the degree of residual presentation of SNPN
relative to SNP seems to be inconsistent with our failure to
detect SNPN lacking one or both N-linked oligosaccha-
rides by SDS-PAGE analysis of mAb-collected material.
Instead, we believe that the residual presentation of SNPN
reflects the generation of peptides from defective ribosomal
products (DRiPs; 42), misfolded, possibly truncated forms
of SNPN that are not inserted into the ER and are pro-
cessed by the standard cytosolic route.
In conclusion, the present findings expand the possible
mechanisms underlying the presentation of secreted and
membrane-bound proteins. It will be important to test in
future experiments whether the results we describe are lim-
ited to cytosolic proteins artificially routed to the secretory
pathway, or also apply to naturally exported proteins that
have evolved to be resistant to secretory proteases. The ma-
jor mode of peptide generation from any given exported
protein must be determined on a case by case basis until
general principles have been more firmly established.
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